SNWV

Business Context and Reporting Period

Company: SANUWAVE Health, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Business Overview: An emerging global regenerative medicine company focused on non-invasive, biological response activating devices (PACE technology) for tissue repair, wound healing, orthopedic, and cardiac applications. The company is currently in the development and commercialization phase, with no profitable operations from continuing activities.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth (Q3): Revenues increased 106% to $278,212 in Q3 2010 compared to $134,771 in Q3 2009, driven by the European launch of the orthoPACE device. However, gross margin decreased from 77% to 61% due to lower margins on demonstration units and higher freight costs.
• Revenue Stability (YTD): Nine-month revenues remained flat at $538,540 (2010) vs. $538,818 (2009).
• Increased Losses (YTD): Net loss from continuing operations widened to $8.4 million for the nine months ended Sep 30, 2010, compared to $6.5 million in the prior year. This excludes a $2.5 million gain from the sale of the veterinary division in 2009.
• Expense Increases:
  • Depreciation: Increased 233% in Q3 and 256% YTD due to the reclassification of Ossatron assets from discontinued to continuing operations, restarting depreciation.
  • Stock-Based Compensation: Increased significantly to $1.39 million YTD (vs. $0.59 million in 2009) due to new option grants.
  • Interest Expense: Increased 41% YTD to $731,771 due to new promissory notes and related party debt.
• Liquidity Deterioration: Cash decreased from $1.79 million (Dec 31, 2009) to $0.39 million (Sep 30, 2010). Current liabilities surged to $10.8 million, creating a significant working capital deficiency.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern Warning: The filing explicitly states substantial doubt about the company's ability to continue as a going concern due to recurring losses and a working capital deficiency of $9.65 million. Continued operations depend on future equity or debt financing.
• Clinical Progress: Completed patient follow-up for the dermaPACE diabetic foot ulcer study (206 patients); expects to report results in Q4 2010 and file a PMA with the FDA in Q1 2011. Launched orthoPACE in Europe in June 2010.
• Financing Activity: Issued $2.45 million in promissory notes during the nine-month period. Subsequent to quarter-end (Oct 2010), these notes were converted into equity units. Also raised $300,000 in September and $500,000 in October via private placements.
• Discontinued Operations: The veterinary division was sold in June 2009. Results are reported separately; no income from discontinued operations was recorded in 2010.
• Legal Proceedings: Involved in a breach of contract lawsuit (Bone & Joint Treatment Centers of America) seeking over $3 million; defense is being handled by HealthTronics.

Investor Verification Checklist

• Capital Sufficiency: Verify the status of the $9.65 million working capital deficiency and the company's ability to secure the additional financing required to fund operations through 2011.
• Clinical Trial Results: Monitor the Q4 2010 release of top-line results for the dermaPACE study, which is critical for future FDA approval and commercialization.
• Debt Conversion: Confirm the final terms and dilution impact of the subsequent conversion of $2.5 million in promissory notes into equity units.
• Margin Sustainability: Assess whether the 61% gross margin in Q3 2010 is sustainable or if it was artificially depressed by demonstration unit sales and freight costs.
• Legal Exposure: Review the status of the pending $3 million lawsuit to ensure no material adverse judgment is imminent.